Earnings call transcript: Sumitomo Chemical H1 2026 profit jumps, but shares fall 9.5%

Sumitomo Chemical’s first-half core operating income rose 32.9% year over year to JPY 144.5 billion, and net income increased 109.3% to JPY 82.9 billion; the company raised its FY 2026 core operating income forecast to JPY 270 billion, up JPY 55 billion, and annual dividend guidance to JPY 17 per share. Semiconductor materials and specialty pharmaceuticals were strong, while overseas crop protection recovery was delayed and Middle East uncertainty remained a risk. Shares fell 9.47% to $511.5 after the report, indicating a negative investor response despite the stronger results and higher guidance.

Analysis

The key earnings-quality issue is that the upgrade is not yet evidence of a uniformly stronger run-rate. Essential & Green Materials supplied a large portion of the first-half improvement, with inventory valuation gains and Petro Rabigh recovery exposed to commodity prices and Middle East operating risk. That makes the raised full-year target vulnerable to reversal even if reported core income looks stronger. Meanwhile, the sales bridge is a warning: price and FX supported revenue while volume declined, so broad-based demand acceleration is not established.

The second-half setup is asymmetric. Management’s ¥150/$ assumption is stronger yen than the first-half average, removing some translation support; semiconductor materials growth must increasingly offset weaker display shipments and higher fixed costs. Agro remains a separate risk: farmer credit constraints and weather could defer crop-protection demand beyond the forecast window. The dividend increase is modest relative to the stated ambition to restore the prior high, and should not be treated as a firm payout trajectory while visibility remains limited.

The balance-sheet improvement is partly supported by Sumitomo Pharma’s capital raise, not solely retained operating cash generation. Also, reported net income benefits do not flow one-for-one to parent shareholders given non-controlling interests. The share-price decline may reflect investors discounting temporary gains rather than rejecting the semiconductor/pharma growth story outright. Without valuation, volume data, or peer performance, the decline alone does not establish an attractive entry point.

Key Decisions for Investors

• Near term: avoid chasing the earnings upgrade; use any rebound to trim or hedge Sumitomo Chemical exposure rather than initiate an aggressive fresh short after the sharp selloff. Reassess once the next results clarify recurring earnings excluding inventory gains and Petro Rabigh.
• Over the next 1–3 months, track Petro Rabigh’s operating contribution, naphtha-related inventory effects, and the yen. A material reversal in those supports would falsify the bull case for the guidance upgrade; stable operations and earnings delivery under the company’s stronger-yen assumption would reduce the downside case.
• Treat semiconductor materials as the structural upside, but require evidence that shipment growth converts into segment profit after capacity, labor, and feedstock costs. If growth persists while display weakness remains contained, reconsider relative exposure versus more focused semiconductor-materials businesses; do not assume the segment’s current strength guarantees consolidated earnings growth.
• Keep agro recovery as a watch item, not a near-term catalyst: look for improving overseas orders and customer purchasing in Latin America and India. Further delays would pressure forecast credibility; a recovery without additional discounting would support the view that the market has over-penalized the shares.